13235-83-1

Basic information

• Product Name: 1-(4-bromophenyl)propan-2-amine
• Synonyms: 1-(4-bromophenyl)propan-2-amine;4-BROMO-A-METHYL-BENZENEETHANAMINE;BenzeneethanaMine, 4-broMo-a-Methyl-;Benzeneethanamine,4-bromo-α-methyl-
• CAS NO: 13235-83-1
• Molecular Formula: C₉H₁₂BrN
• Molecular Weight: 214.105
• Mol File: 13235-83-1.mol

Chemical Properties

• Boiling Point: 272.2°C at 760 mmHg
• Flash Point: 118.5°C
• Appearance: /
• Density: 1.346g/cm³
• Vapor Pressure: 0.00615mmHg at 25°C
• Refractive Index: 1.562
• PKA: 9.76±0.10(Predicted)
• CAS DataBase Reference: 1-(4-bromophenyl)propan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-bromophenyl)propan-2-amine(13235-83-1)
• EPA Substance Registry System: 1-(4-bromophenyl)propan-2-amine(13235-83-1)

Safety Data

• Hazardous Substances Data: 13235-83-1(Hazardous Substances Data)

Usage

Uses

Used in Research Applications:
1-(4-bromophenyl)propan-2-amine is used as a research chemical for studying the effects of psychoactive substances on the central nervous system. Its unique structure allows scientists to investigate the mechanisms of action and potential therapeutic applications of amphetamine-like compounds.
Used in Pharmaceutical Development:
Although not approved for medical use, 1-(4-bromophenyl)propan-2-amine may be utilized in the development of new pharmaceuticals targeting the central nervous system. Its stimulant and entactogenic properties could potentially be harnessed for the treatment of certain neurological or psychiatric disorders, provided that safety concerns are adequately addressed.
Used in Forensic Toxicology:
1-(4-bromophenyl)propan-2-amine is used as a reference compound in forensic toxicology for the identification and analysis of substances found in biological samples. Its unique chemical structure aids in the detection and quantification of controlled substances in cases of drug abuse or intoxication.

InChI:InChI=1/C9H12BrN/c1-7(11)6-8-2-4-9(10)5-3-8/h2-5,7H,6,11H2,1H3

Upstream product

• 744221-06-5 1-bromo-4-(2-chloro-propyl)-benzene 
• 21892-60-4 1-(p-Bromphenyl)-2-nitro-1-propen 
• 131981-75-4 (E)-1-bromo-4-(2-nitroprop-1-en-1-yl)benzene 
• 1122-91-4 4-bromo-benzaldehyde 
• 108-86-1 bromobenzene 
• 1310-73-2 sodium hydroxide 
• 6186-22-7 4-bromophenyl acetone 
• 7732-18-5 water 
• 4489-23-0 1-bromo-4-(prop-1-en-1-yl)benzene 

Downstream Products

• 109971-39-3 N-isopropyl p-bromoamphetamine 
• 1146547-07-0 C₁₇H₁₈BrNO₂ 
• 1233524-85-0 methyl (1-(4-bromophenyl)propan-2-yl)carbamate 
• 1223717-97-2 N-[2-(4'-bromophenyl)-1-methylethyl]-2-methoxyacetamide 
• 869567-02-2 (S)-(+)-1-(4'-bromo)phenyl-2-propanamine 
• 869567-01-1 (R)-(-)-1-(4'-bromo)phenyl-2-propanamine 
• 1446021-11-9 N-(1-(4-(azetidin-3-yl)phenyl)propan-2-yl)acetamide 
• 1446021-05-1 tert-butyl 3-(4-(2-acetamidopropyl)phenyl)azetidine-1-carboxylate 
• 1446020-02-5 C₂₂H₂₆F₂N₄O₂ 
• 1446019-91-5 C₂₄H₂₅ClN₄O 
• 1446019-65-3 C₂₂H₂₉N₃O₂ 
• 1446019-89-1 N-(1-(4-(1-(5-bromopyrimidin-2-yl)azetidin-3-yl)phenyl)propan-2-yl)acetamide 
• 1446019-54-0 N-(1-(4-(1-(4-propoxyphenyl)azetidin-3-yl)phenyl)propan-2-yl)acetamide 
• 1197684-85-7 N-[2-(4-bromophenyl)-1-methyl-ethyl]acetamide 

Relevant articles and documents

Direct Access to Primary Amines from Alkenes by Selective Metal-Free Hydroamination

Direct and selective synthesis of primary amines from easily available precursors is attractive yet challenging. Herein, we report the rapid synthesis of primary amines from alkenes via metal-free regioselective hydroamination at room temperature. Ammonium carbonate was used as ammonia surrogate for the first time, allowing for efficient conversion of terminal and internal alkenes into linear, α-branched, and α-tertiary primary amines under mild conditions. This method provides a straightforward and powerful approach to a wide spectrum of advanced, highly functionalized primary amines which are of particular interest in pharmaceutical chemistry and other areas.

Protein arginine methyltransferase 5 (PRMT5) inhibitor, pharmaceutical products thereof, and methods thereof

The present invention provides a PRMT5 inhibitor of formula (I); R1 is a non-hydrogen monovalent group; W is a direct bond or-NH-; T, U and V are independently from each other selected from C and N; R2 is H or halogen; m is 1 or 2; X is carbon, nitrogen or oxygen; Y is C or N; Z is a direct bond or carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a divalent spiro-forming group or adivalent bridge-forming group; and n is 1 or 2, and represents a single or double bond. The present invention also provides pharmaceutical products comprising the PRMT5 inhibitor and use thereof in the treatment of proliferative disorders such as cancer, metabolic disorders, hematological disorders, autoimmune diseases and inflammatory diseases.

INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF

The present invention provides PRMT5 inhibitors of Formula (I), wherein R1 is a non-hydrogen monovalent group; W is a direct bond or -NH-; T, U, and V are independently of each other selected from C and N; R2 is H or a halo; m is 1 or 2; X is a carbon, a nitrogen, or an oxygen; Y is C or N; Z is a direct bond or a carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group; n is 1 or 2; and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided.

New azetidine derivatives, pharmaceutical compositions and uses thereof

The invention relates to new azetidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

The invention relates to new azetidine derivatives of the formula (I), to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

New compounds, pharmaceutical compositions and uses thereof

The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Enzymatic enantiomeric resolution of phenylethylamines structurally related to amphetamine

Both enantiomers of several phenylethylamines, structurally related to amphetamine, have been prepared in good yields and excellent enantiomeric purity by enzymatic kinetic resolution using CAL-B and ethyl methoxyacetate as the acyl donor. In the case of the 4-hydroxyderivative of amphetamine (compound 4i), the S enantiomer racemized possibly in a dynamic kinetic resolution (DKR) under the enzymatic conditions used. The Royal Society of Chemistry 2011.

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

CCR10 ANTAGONISTS

The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compounds of formula (I) and compositions thereof to treat various diseases and disorders in a patient. The invention also relates to processes for preparing the compounds of formula (I) and intermediates useful in these processes.

Binding of Phenylalkylamine Derivatives at 5-HT1C and 5-HT2 Serotonin Receptors: Evidence for a Lack of Selectivity

Certain phenyalkylamine derivatives have been considered to bind selectively at 5-HT2 serotonin receptors.It is now recognized that the most widely used derivatives, i.e., 1-(2,5-dimethoxy-4-X-phenyl)-2-aminopropanes where X = Me (DOM), Br (DOB), and I (DOI) (1-3, respectively) also bind at the more recently identified population of serotonin 5-HT1C receptors.The purpose of the present investigation was to determine whether simple phenylalkylamines bind selectively at one population of receptors over the other.An examination of 34 derivatives reveals (i) similar structure-affinity relationships and (ii) a significant correlation (r = >0.9, n = 25) between 5-HT1C and 5-HT2 affinity.None of the compounds included in the present study displayed more than a 10-fold selectivity for one population of these receptors over the other; the results suggest that these compounds (including the widely used 5-HT2 agonists DOB and DOI) are 5-HT1C/5-HT2 agents.